Yahoo Finance

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order ...

COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value ...
Nasdaq

FDA Approves ArbliTM, the First Ready-to-Use Oral Liquid Formulation of Losartan, from Scienture Holdings, Inc.

Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension, at a ...
Yahoo Finance

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan ...

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced ...

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned ...
Business Wire

Nautilus Neurosciences, Inc. Announces the Sale of CAMBIA® (Diclofenac Potassium for Oral Solution) to Depomed, Inc. for Total Consideration of Up to $53.7 Million

BEDMINSTER, N.J.--(BUSINESS WIRE)--Nautilus Neurosciences, Inc. has completed a transaction for the sale of the U.S. and Canadian rights to CAMBIA® (diclofenac potassium for oral solution) to Depomed, ...